Research profile
Retatrutide
Retatrutide activates receptors for GIP, GLP-1, and glucagon. Researchers are evaluating it for chronic weight management.
- Investigational clinical research
- Evaluation only
Amnavero
Retatrutide
What the research found
A randomized phase 2 study enrolled 338 adults. At 48 weeks, mean weight change in the highest-dose group was −24.2%, compared with −2.1% with placebo.
What remains uncertain
This was a phase 2 result. The drug remains investigational in the United States, and the study did not establish its long-term safety.